珍宝岛2025年预亏超10亿元，股价连续下跌

Group 1 - The company, Zhenbao Island, announced a forecast for 2025 indicating a net profit loss of between 1.012 billion to 1.173 billion yuan, marking its first annual loss since its listing, primarily due to delayed procurement of traditional Chinese medicine and healthcare cost control, leading to a 53% year-on-year revenue decline and a 93% drop in gross profit [1] - Revenue has continuously declined from a peak of 4.219 billion yuan in 2022, with only 919 million yuan reported in the first three quarters of 2025, representing a 54.73% year-on-year decrease, while the net profit excluding non-recurring items has turned negative multiple times since 2022, indicating weakened core profitability [1] - The company's investment in innovative drug research and development is progressing slowly, making it difficult to support performance in the short term [1] Group 2 - The stock price of Zhenbao Island has experienced a continuous decline over the past seven days, with a total drop of 3.91%, closing at 8.12 yuan on February 12, down 1.81% for the day, and showing a net outflow of 11.388 million yuan in principal funds on the same day, with retail investors accounting for 36% [2] - Technical analysis indicates that the stock is in a bearish trend, with the moving average system showing a bearish arrangement, a resistance level at 9.33 yuan, and a support level at 7.96 yuan, underperforming compared to the pharmaceutical and biological sector and the broader market [2] Group 3 - On February 6, 2026, the controlling shareholder, Chuangda Group, announced a reduction in its shareholding from 56.98% to 55.86% due to the conversion of exchangeable bonds, although control has not changed [3] - As of February 10, Chuangda Group has pledged 80.48% of its shares, with an additional 1.17 million shares pledged to secure the exchangeable bond guarantee [3] - On February 6, the Ministry of Industry and Information Technology and other departments released the "High-Quality Development Plan for Traditional Chinese Medicine Industry (2026-2030)," emphasizing the upgrade of the entire industry chain, which aligns with Zhenbao Island's layout, but the short-term impact on performance is limited [3]